-
Australia Opens The Door for SKY-0515: Skyhawk Seeks Provisional Approval for Its Oral HD Drug
Latest News
-
The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
⏱️ 10 min read | The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure shared in an update that current Phase 1/2 data weren’t enough for the agency. A new randomized, sham-controlled trial may be required.
-
Huntexil for symptoms of Huntington's disease: where are we now?
Two clinical trials in Europe and the USA have suggested a new drug, Huntexil, might improve movements in HD. The nex
-
Minocycline: the end of the road?
DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.
-
TRACK-HD reveals significant changes in pre-symptomatic HD mutation carriers and patients
The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation carriers
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Alnylam Pharmaceuticals
Expected:
2026
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
Novartis/PTC Therapeutics
Expected:
Not disclosed
Updates from the ongoing placebo-controlled Phase 2/3 FALCON-HD trial
Skyhawk Therapeutics
Expected:
Not disclosed